CGEN Compugen Ltd Forecast, Technical & Fundamental Analysis
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy... Show more
CGEN is expected to report earnings to rise 17.14% to -8 cents per share on November 16
Q3'26
Est.
$-0.08
Q2'26
Beat
by $0.01
Q1'26
Missed
by $0.01
Q4'25
Beat
by $0.68
Q3'25
Est.
$-0.07
The last earnings report on August 03 showed earnings per share of -7 cents, beating the estimate of -7 cents. With 197.34K shares outstanding, the current market capitalization sits at 246.68M.
A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with ORMP. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then ORMP could also see price increases.
CGEN in -5.88% downward trend, sliding for three consecutive days on July 29, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CGEN declined for three days, in of 314 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
CGEN broke above its upper Bollinger Band on August 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CGEN entered a downward trend on August 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 18, 2026. You may want to consider a long position or call options on CGEN as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CGEN just turned positive on August 11, 2026. Looking at past instances where CGEN's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
CGEN moved above its 50-day moving average on July 30, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CGEN crossed bullishly above the 50-day moving average on July 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CGEN advanced for three days, in of 233 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.792) is normal, around the industry mean (20.145). P/E Ratio (6.895) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (3.344) is also within normal values, averaging (444.692).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
